MiR-186 inhibits proliferation, migration, and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1

Huang, Tonghai; Wang, Guangsuo; Yang, Lin; Peng, Bin; Wen, Yuanyuan; Ding, Guanggui; Wang, Zheng

doi:10.3233/cbm-170670

Cited by 32 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, the upregulation of TM4SF1-AS1 identified in our recurrent samples may result in the overexpression of STEAP2 and possible lower expression of miR-186 in OvCa. is theory was validated in our study and previous studies: extensive evidence had suggested that miR-186 was a tumor suppressor gene, with a downregulated expression level in cancer tissues, cells [30,31], and blood of recurrent oral squamous cell carcinoma patients compared with controls [32], including OvCa [33]. Overexpression of miR-186 into cancer cells significantly inhibited proliferation, invasion, metastasis [29,34,35], and induced mesenchymal-to-epithelial transition, G1 cell cycle arrest, and cell apoptosis [33].…”

Section: Discussionsupporting

confidence: 80%

Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Ovarian cancer (OvCa) is an intractable gynecological malignancy due to the high recurrence rate. Several molecular biomarkers have been previously screened for early identifying patients with a high recurrence risk and poor prognosis. However, all the known studies focused on a single type of RNAs, not integrating various types. This study was to construct a new multi-RNA-based model to predict the recurrence and prognosis for OvCa patients by using the messenger RNA (mRNA, including long noncoding RNA (lncRNA)) and microRNA (miRNA) sequencing data of The Cancer Genome Atlas database. After univariate Cox regression and least absolute shrinkage and selection operator analyses, a multi-RNA-based signature (2 miRNAs: hsa-miR-508, hsa-miR-506; 1 lncRNA: TM4SF1-AS1; 11 mRNAs: MAGI3, SLAMF7, GLI2, PDK1, ARID3A, PLEKHG4B, TNFAIP8L3, C1QTNF3, NDUFAF1, CH25H, TMEM129) was generated and used to establish a risk score model. The high- and low-risk patients classified by the median risk score exhibited significantly different recurrence risks (89% versus 61%, p<0.001) and survival time (the area under the receiver operating characteristic curve (AUC) = 0.901 for 5-year disease-free survival (DFS)). This risk model was independent of other clinical features and superior to pathologic staging for DFS prediction (AUC, 0.906 versus 0.524; C-index, 0.633 versus 0.510). Furthermore, some new interaction axes were revealed to explain the possible functions of these RNAs (competing endogenous RNA: TM4SF1-AS1-miR-186-STEAP2, LINC00536-miR-508-STEAP2, LINC00475-miR-506-TMEM129; coexpression: LINC00598-PLEKHG4B). In conclusion, this multi-RNA-based risk model may be clinically useful to stratify OvCa patients with different recurrence risks and survival outcomes and included RNAs may be potential therapeutic targets.

show abstract

Section: Discussionsupporting

confidence: 80%

Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Feng et al confirmed miR-186 significantly upregulated in lung adenocarcinoma samples and cells, in comparison with the adjacent noncancerous samples and normal lung epithelial cells BEAS-IB (13). However, several groups reported that the levels of miR-186 were markedly decreased in NSCLC samples and cells (14)(15)(16)(17)(18)(19)(20). Prostate cancer is the most common non-skin cancer in males, with there being ∼1.6 million cases worldwide annually (60).…”

Section: Altered Expressions Of Mir-186 In Different Cancersmentioning

confidence: 99%

“…In the five types of controversial cancers, there were many reports that miR-186 served as a tumor suppressor miRNA by target multiple oncogenes, which was contradictory to the previous statements. In NSCLS, miR-186 inhibited cell proliferation by targeting CCND1 (coding cyclins D1), CDK2, CDK6 (14), CDK1 (20), SIRT6 (15), and ROCK1 (16), inhibited migration and invasion via targeting ROCK1 (16), MAP3K2 (17), YY1 (18), and Cdc42 (19), and induced cell apoptosis via targeting SIRT6 (15). The cyclin-CDK complexes promotes cellular proteins phosphorylation, then drive the progress of cell cycle, which is essential in tumorigenesis (71).…”

Section: Mir-186 As a Tumor Suppressor Mirnamentioning

confidence: 99%

The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA

et al. 2020

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of small non-coding RNAs which regulate gene expression at post-transcriptional level. Alterations of miR-186 expression were demonstrated in numerous cancers, shown to play a vital role in oncogenesis, invasion, metastasis, apoptosis, and drug resistance. MiR-186 was documented as a tumor suppressor miRNA in the majority of studies, while conflicting reports verified miR-186 as an oncomir. The contradictory role in cancers may impede the application of miR-186, as well as other dual-functional miRNAs, as a diagnostic and therapeutic target. This review emphasizes the alterations and functions of miR-186 in cancers and discusses the mechanisms behind the contradictory findings. Among these, target abundance and dose-dependent effects of miR-186 are highlighted. The paper aims to review the challenges involved in developing diagnostic and therapeutic strategies for cancer treatment based on dual-functional miRNAs.

show abstract

“…For instance, miR-125b inhibits the expression of MMP13 and suppresses CSCC cell proliferation, migration and invasion (11). miR-186 is an important member of cancer-associated miRs and has been reported to generally serve a tumour suppressive role in various types of human cancer, including chronic myeloid leukaemia (12), colorectal cancer (13), gastrointestinal stromal tumour (14), lung cancer (15), liver cancer (16), cervical cancer (17), and gastric cancer (18). miR-186 inhibits the proliferation, metastasis and epithelial-to-mesenchymal transition of colorectal cancer cells by targeting ZEB1 (13).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑186 promotes cell proliferation and inhibits cell apoptosis in cutaneous squamous cell carcinoma by targeting RETREG1

Liu

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

MicroRNAs (miRs), a class of small non-coding RNAs, have been demonstrated to be involved in the development and progression of human malignancies, including cutaneous squamous cell carcinoma (CSCC). miR-186 serves a suppressive role in certain common types of human cancer; however, its exact function in CSCC has not been reported previously. In the present study, the expression of miR-186 was significantly increased in CSCC tissues compared with adjacent non-tumour tissues. Overexpression of miR-186 significantly promoted CSCC cell proliferation while inhibiting cell apoptosis. Reticulophagy regulator 1 (RETREG1), a gene that is significantly downregulated in CSCC tissues and cell lines, was identified as a novel target of miR-186. In addition, the expression of RETREG1 was inversely correlated with miR-186 expression in CSCC tissues. Furthermore, the expression of RETREG1 was negatively regulated by miR-186 in CSCC cells, and restoration of RETREG1 attenuated the effects of miR-186 on CSCC cells. Taken together, the results of the current study suggest that miR-186 serves an oncogenic role in CSCC and may be used as a potential therapeutic target for the treatment of this disease.

show abstract

MiR-186 inhibits proliferation, migration, and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1

Abstract: Our results suggest that miR-186 and its target gene (YY1) could possibly serve as new prognostic biomarkers and therapeutic targets for treating NSCLC in humans.

Cited by 32 publications

References 29 publications

Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients

Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients

The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA

MicroRNA‑186 promotes cell proliferation and inhibits cell apoptosis in cutaneous squamous cell carcinoma by targeting RETREG1

Contact Info

Product

Resources

About